InvesTrust Has $5.09 Million Holdings in Eli Lilly and Company $LLY

InvesTrust lessened its stake in Eli Lilly and Company (NYSE:LLY) by 39.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,528 shares of the company’s stock after selling 4,313 shares during the quarter. Eli Lilly and Company makes up 2.0% of InvesTrust’s holdings, making the stock its 15th biggest position. InvesTrust’s holdings in Eli Lilly and Company were worth $5,089,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Hobbs Wealth Management LLC increased its holdings in shares of Eli Lilly and Company by 0.8% during the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company’s stock valued at $1,205,000 after acquiring an additional 12 shares in the last quarter. Hixon Zuercher LLC increased its holdings in shares of Eli Lilly and Company by 0.7% during the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company’s stock valued at $1,477,000 after acquiring an additional 12 shares in the last quarter. O Brien Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 25.5% during the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock valued at $49,000 after acquiring an additional 12 shares in the last quarter. Ascent Capital Management LLC increased its holdings in shares of Eli Lilly and Company by 2.5% during the first quarter. Ascent Capital Management LLC now owns 495 shares of the company’s stock valued at $409,000 after acquiring an additional 12 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners increased its holdings in shares of Eli Lilly and Company by 2.7% during the first quarter. Tennessee Valley Asset Management Partners now owns 493 shares of the company’s stock valued at $407,000 after acquiring an additional 13 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft decreased their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a report on Monday, August 11th. Guggenheim decreased their price objective on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a report on Wednesday, August 13th. Daiwa Capital Markets downgraded Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective for the company. in a report on Sunday, August 17th. Leerink Partners restated a “market perform” rating and set a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. Finally, DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $941.35.

Eli Lilly and Company Trading Down 0.2%

Shares of Eli Lilly and Company stock opened at $754.90 on Friday. The stock has a fifty day simple moving average of $741.03 and a 200 day simple moving average of $777.36. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $942.35. The company has a market capitalization of $714.48 billion, a P/E ratio of 49.34, a price-to-earnings-growth ratio of 1.05 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the company posted $3.92 earnings per share. Eli Lilly and Company’s revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were issued a dividend of $1.50 per share. The ex-dividend date was Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.8%. Eli Lilly and Company’s dividend payout ratio is 39.22%.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director Gabrielle Sulzberger acquired 117 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director directly owned 2,703 shares of the company’s stock, valued at $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director J Erik Fyrwald acquired 1,565 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the purchase, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 4,514 shares of company stock worth $2,894,841. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.